(Source: arGEN-X NV) May 21, 2015: arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions Breda, the Netherlands/Ghent, Belgium and Ballerup, Denmark - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, and LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, today announced an alliance in which they will collaborate to develop innovative antibody-based solutions for the treatment of chronic inflammation underlying many skin conditions. Under the terms of...